Effect of high-dose oral N-acetylcysteine versus placebo on serum level of oxidative and nirtosative stress and clinical outcomes in patients with ischemic stroke
Phase 2
- Conditions
- ischemic stroke.Cerebral infarction
- Registration Number
- IRCT20150629022965N16
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
Age: 18 to 85 years old
Ischemic stroke Stroke for the first time
Local neurologic disorder
Patients who have been admitted for the first 24 hours after the stroke
Exclusion Criteria
Pregnancy or breastfeeding
Inflammatory disease
Asthma
History of anaphylaxis shock
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does high-dose NAC modulate in IRCT20150629022965N16 ischemic stroke patients?
How does high-dose oral NAC compare to standard-of-care neuroprotectants in reducing oxidative stress post-ischemic stroke?
Which biomarkers correlate with improved clinical outcomes in IRCT20150629022965N16 NAC-treated cerebral infarction patients?
What adverse events are associated with high-dose NAC in phase II ischemic stroke trials and how are they managed?
Are there combination therapies involving NAC and antiplatelet agents for cerebral infarction in phase II studies?